[go: up one dir, main page]

WO2019126364A3 - Compositions and methods related to nicotine addiction and cessation - Google Patents

Compositions and methods related to nicotine addiction and cessation Download PDF

Info

Publication number
WO2019126364A3
WO2019126364A3 PCT/US2018/066562 US2018066562W WO2019126364A3 WO 2019126364 A3 WO2019126364 A3 WO 2019126364A3 US 2018066562 W US2018066562 W US 2018066562W WO 2019126364 A3 WO2019126364 A3 WO 2019126364A3
Authority
WO
WIPO (PCT)
Prior art keywords
nicotine
cessation
compositions
nicotine addiction
methods related
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/066562
Other languages
French (fr)
Other versions
WO2019126364A2 (en
Inventor
Kim D. Janda
Olivier GEORGE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scripps Research Institute
Original Assignee
Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Institute filed Critical Scripps Research Institute
Publication of WO2019126364A2 publication Critical patent/WO2019126364A2/en
Publication of WO2019126364A3 publication Critical patent/WO2019126364A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01328—Nicotine blue oxidoreductase (1.1.1.328)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides nicotine-degrading fusion enzymes that are comprised of a N-terminally truncated nicotine-degrading enzyme (e.g., NicA2) and a fusion partner (e.g., an albumin binding moiety). The invention also provides therapeutic methods of using the fusion enzymes for promoting nicotine cessation, treating nicotine addiction or nicotine poisoning, and prevent relapse.
PCT/US2018/066562 2017-12-19 2018-12-19 Compositions and methods related to nicotine addiction and cessation Ceased WO2019126364A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762607423P 2017-12-19 2017-12-19
US62/607,423 2017-12-19
US201862765355P 2018-08-20 2018-08-20
US62/765,355 2018-08-20

Publications (2)

Publication Number Publication Date
WO2019126364A2 WO2019126364A2 (en) 2019-06-27
WO2019126364A3 true WO2019126364A3 (en) 2020-03-26

Family

ID=66993906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/066562 Ceased WO2019126364A2 (en) 2017-12-19 2018-12-19 Compositions and methods related to nicotine addiction and cessation

Country Status (1)

Country Link
WO (1) WO2019126364A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3577218A1 (en) 2017-02-03 2019-12-11 Antidote Therapeutics, Inc. Novel nicotine degrading enzyme variants
US12318433B2 (en) 2018-08-02 2025-06-03 Antidote Therapeutics, Inc. Nicotine degrading enzyme variants

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150291668A1 (en) * 2012-10-25 2015-10-15 Affibody Ab Abd binding polypeptide
WO2017023904A2 (en) * 2015-08-04 2017-02-09 The Scripps Research Institute Nicotine-degrading enzymes for treating nicotine addiction and nicotine poisoning
WO2017167250A1 (en) * 2016-04-01 2017-10-05 上海交通大学 Enzyme and application thereof
WO2018144879A1 (en) * 2017-02-03 2018-08-09 Antidote Therapeutics, Inc. Novel nicotine degrading enzyme variants

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150291668A1 (en) * 2012-10-25 2015-10-15 Affibody Ab Abd binding polypeptide
WO2017023904A2 (en) * 2015-08-04 2017-02-09 The Scripps Research Institute Nicotine-degrading enzymes for treating nicotine addiction and nicotine poisoning
US20190015484A1 (en) * 2015-08-04 2019-01-17 The Scripps Research Institute Nicotine-degrading enzymes for treating nicotine addiction and nicotine poisoning
WO2017167250A1 (en) * 2016-04-01 2017-10-05 上海交通大学 Enzyme and application thereof
WO2018144879A1 (en) * 2017-02-03 2018-08-09 Antidote Therapeutics, Inc. Novel nicotine degrading enzyme variants

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MCCLURE, EA ET AL.: "An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers", AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, vol. 41, no. 1, January 2015 (2015-01-01), pages 52 - 56 *
PENTEL, PR ET AL.: "The nicotine-degrading enzyme NicA2 reduces nicotine levels in blood, nicotine distribution to brain, and nicotine discrimination and reinforcement in rats", BMC BIOTECHNOLOGY, vol. 18, no. 46, 24 July 2018 (2018-07-24), pages 1 - 14, XP055694589 *
TARARINA, MA ET AL.: "Structural Analysis Provides Mechanistic Insight into Nicotine Oxidoreductase from Pseudomonas putida", BIOCHEMISTRY, vol. 55, no. 48, 6 December 2016 (2016-12-06), pages 6595 - 6598, XP055467672, DOI: 10.1021/acs.biochem.6b00963 *
XUE, S ET AL.: "An Enzymatic Advance in Nicotine Cessation Therapy", CHEMICAL COMMUNICATIONS, vol. 54, no. 14, 13 February 2018 (2018-02-13), pages 1686 - 1689, XP055694590 *

Also Published As

Publication number Publication date
WO2019126364A2 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
PH12020551997A1 (en) Psma binding agents and uses thereof
MX2022010490A (en) USEFUL COMPOSITIONS FOR INTERNALIZATION ENZYMES.
EP3835322A3 (en) Anti-b7-h3 antibodies and antibody drug conjugates
WO2019241430A3 (en) Antibody-oligonucleotide conjugates
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
WO2007115837A3 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
WO2018151821A8 (en) Antibodies to alpha-synuclein and uses thereof
WO2020172631A3 (en) Untargeted and targeted il-10 fc-fusion proteins
MX2022009302A (en) Il-7rî± binding compounds.
AU2018271872A1 (en) A protein binding NKG2D, CD16 and ROR1 or ROR2
EP4527466A3 (en) Anti-dll3 chimeric antigen receptors and uses thereof
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
ATE518010T1 (en) ACTIVE SURFACE COUPLED POLYMERASES
WO2022082073A3 (en) Compositions and methods for muc18 targeting
EP4372002A3 (en) Proximity-based sortase-mediated protein purification and ligation
AU2018337947A1 (en) Compositions and methods for predicting response to NaPi2b-targeted therapy
MX2023014458A (en) Anti-ccr8 antibodies and uses thereof.
MX2019009541A (en) Proteins binding psma, nkg2d and cd16.
MX2022013938A (en) Peptide tags and binding partners.
SA523451582B1 (en) CCR8 antibodies
WO2017023904A3 (en) Nicotine-degrading enzymes for treating nicotine addiction and nicotine poisoning
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
MX2021006515A (en) Methylobacterium compositions for improving corn yield.
WO2021207433A3 (en) Epitopes of sars-cov-2 neutralizing antibodies
PH12021551422A1 (en) Anti-il-36 antibodies and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18890810

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18890810

Country of ref document: EP

Kind code of ref document: A2